Monitor for any subsequent 13G amendments or a potential conversion to 13D if JPMorgan's intent changes. The passive nature and modest stake size suggest no near-term catalyst.
Price Chart
Executive Summary
JPMorgan Chase & Co. disclosed a passive 5.1% stake in Rhythm Pharmaceuticals via a new Schedule 13G filing, representing 3,563,667 shares as of September 30, 2026. This is a new passive position from a major financial institution, indicating institutional interest but no activist intent.
Key Financial Metrics
Key Facts
- JPMorgan Chase & Co. filed a new Schedule 13G disclosing beneficial ownership of 3,563,667 shares of Rhythm Pharmaceuticals common stock.
- The stake represents 5.1% of shares outstanding as of September 30, 2026.
- The filing is under Rule 13d-1(b), confirming passive intent with no control or influence purpose.
- JPMorgan's holdings include shares held by multiple subsidiaries including J.P. Morgan Securities LLC, JPMorgan Chase Bank, and J.P. Morgan Investment Management Inc.
Financial Impact
Passive 5.1% stake by a large bank; no immediate financial impact on Rhythm's operations or capital structure.
Risk Factors
- JPMorgan could reduce or exit the position without further disclosure until below 5%.
- No indication of activist or strategic intent; filing is purely informational.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000019617-26-000351 |
| Document: 0000019617-26-000351-index.html | 0000019617-26-000351 |
| Document: 0000019617-26-000351.txt | 0000019617-26-000351 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | Press Release | $86.71 | awaiting T+60 | — | $89.47 (+3.18%) |
Oct 13, 2026 13d ago | SC 13G | $86.61 | awaiting T+60 | — | $89.47 (+3.30%) |
Sep 14, 2026 6w ago | 144 | $96.77 | awaiting T+60 | — | $89.47 (+7.54%) |
Aug 17, 2026 10w ago | Insider Cluster | $115.25 | awaiting T+60 | — | $89.47 (+22.37%) |
Aug 17, 2026 10w ago | Insider Cluster | $115.25 | awaiting T+60 | — | $89.47 (−22.37%) |
Aug 4, 2026 12w ago | 8-K | $105.78 | awaiting T+60 | — | $89.47 (−15.42%) |
Aug 4, 2026 12w ago | Press Release | $105.78 | awaiting T+60 | — | $89.47 (−15.42%) |
Jul 8, 2026 15w ago | Press Release | $115.48 $92.83 | ▼ −19.61% | ▼ −21.25% | $89.47 (−22.52%) |
Jun 22, 2026 18w ago | 144 | $106.19 $98.01 | ▼ −7.70% | ▼ −10.95% | $89.47 (−15.75%) |
Jun 15, 2026 19w ago | 8-K | $89.72 $102.20 | ▲ +13.91% | ▲ +12.91% | $89.47 (−0.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers